C&G Editor in Chief, Erin Harris

1. The Center For Breakthrough Medicines’ Newest Leaders Talk Advanced Therapy Development, Manufacturing 4/1/2021

   I had the opportunity to connect with four of The Center for Breakthrough Medicines' newest leaders about their respective roles, the future of manufacturing, and much more. 

2. Inside Repertoire Immune Medicines’ T Cell Recognition Of SARS-CoV-2 4/1/2021

   Anthony Coyle, Ph.D., President, Research and Development at Repertoire Immune Medicines explains the company's DECODE platform and the role it played in the T cell recognition of SARS-CoV-2. 

3. Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19 3/23/2021

   Tevogen Bio recently announced its partnership with BioCentriq, a New Jersey-based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. 

4. Orchard Therapeutics’ CEO One Year In, Part 2 3/16/2021

   In part one of my sit down with Dr. Bobby Gaspar, CEO of Orchard Therapeutics, I explained how he officially took over the reins on March 18, 2020. You’ll also want to listen in to our podcast with Dr. Gaspar for an update on the company’s pipeline progress gives way to an in-depth discussion on the process challenges his company faces in the production of hematopoietic stem cells to treat neurometabolic disorders, primary immune deficiencies, and blood disorders.

5. Orchard Therapeutics’ CEO One Year In 3/12/2021

   Dr. Bobby Gaspar, CEO of Orchard Therapeutics, officially took over the reins on March 18, 2020. You read the date correctly — Gaspar became CEO at the very beginning of the COVID-19 pandemic. One year later, and despite the global pandemic, Orchard boasts its first commercial approval.

6. Reducing the Manufacturing Costs of Allogeneic Cell Therapies 3/9/2021

   On the heels of our second Cell & Gene Live event sponsored by Invetech, Can Innovation Drive Down Cell Therapy Manufacturing Costs?, here we focus on the strategies that can reduce the manufacturing costs of allogeneic cell therapies. 

7. Immunitas Therapeutics On The Future Of Immuno-Oncology 2/25/2021

   Immunitas Therapeutics' scientific Co-Founder Kai Wucherpfenning, M.D., Ph.D. explains the role robotic automation plays in immunology, the use of single-cell RNA sequencing in their study, as well as the future of immuno-oncology. 

8. Driving Down Costs of Autologous Cell Therapy Manufacturing 2/19/2021

   In this article, we will focus on ways to drive down the cost of manufacturing autologous cell therapies as explained in the Cell & Gene Live event.

9. Codiak Biosciences On The Promise Of Engineered Exosomes For Drug Delivery 2/18/2021

   Here's an inside look at Codiak BioSciences, which launched the first-ever clinical trials of engineered exosomes — nanometer-sized vesicles that shuttle messages between cells.

10. Inside BioCardia’s CardiAMP Cell Therapy 2/8/2021

    Peter Altman, PhD, CEO at BioCardia explains CardiAMP Heart Failure Trial and its best possible outcomes for patients.